Alfredo Budillon, M.D
IRCCS I.N.T. "G. Pascale" · National Cancer Institute, Naples · Experimental Pharmacology, National Cancer Institute Naples
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Alfredo Budillon, M.D as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 07:23 UTC. Open this list on ClinicalTrials.gov
- N/ANCT05817227 · Selenoproteins as Prognostic Markers and Therapeutic Targets in Breast Cancer.National Cancer Institute, Naples · recruiting · Breast Cancer · principal investigator
- Ph2NCT02624128 · Valproic Acid Plus Cisplatin and Cetuximab in Recurrent and/or Metastatic Squamous Cell Carcinoma of Head and NeckNational Cancer Institute, Naples · unknown · Squamous Cell Carcinoma of the Head and Neck · principal investigator
- Ph2NCT02619435 · Regorafenib Monotherapy as Second-line Treatment of Patients With RAS-mutant Advanced Colorectal CancerNational Cancer Institute, Naples · unknown · Advanced Colorectal Cancer · principal investigator
- Ph1NCT00415779 · ZANTE: Zometa and Taxotere in Hormone Refractory Prostate CancerNational Cancer Institute, Naples · completed · Metastatic Prostate Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 07:23 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name.